About
Copy Link
Titles
Research Assistant 2 HSS
Biography
Stephen came to the clinic with a long-held interest in anxiety disorders and OCD. He coordinates studies, conducts clinical assessment and education, facilitates psychedelic study sessions, and trains staff.
Last Updated on January 21, 2025.
Education & Training
- MPH
- University of Connecticut
- BA
- Central Connecticut State University, Psychology
Research
Copy Link
Overview
Medical Research Interests
Anxiety Disorders; Behavior Therapy; Emotions; Health Education
- View Lab Website
Yale OCD Research Clinic
Research at a Glance
Yale Co-Authors
Frequent collaborators of Stephen Kichuk's published research.
Publications Timeline
A big-picture view of Stephen Kichuk's research output by year.
Christopher Pittenger, MD, PhD
Benjamin Kelmendi, MD
Terence Ching, PhD
Brian Zaboski, PhD
Michael Bloch, MD, MS
Geena Fram
18Publications
455Citations
Publications
2025
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Ching T, Stahnke B, Shnayder S, Agin-Liebes G, Adams T, Amoroso L, Baiz O, Belser A, Bohner C, Burke M, D’Amico E, DePalmer G, Eilbott J, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Purohit P, Schaer H, Sierra Y, Witherow C, Pittenger C, Kelmendi B. Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. Frontiers In Psychiatry 2025, 16: 1726818. PMID: 41450831, PMCID: PMC12728583, DOI: 10.3389/fpsyt.2025.1726818.Peer-Reviewed Original ResearchAltmetricConceptsObsessive-compulsive disorderObsessive-compulsive disorder symptomsPsilocybin experienceInterpretative phenomenological analysisSubjective effectsTreatment-refractory obsessive-compulsive disorderRandomized placebo-controlled trialSubjective effects of psilocybinEffects of psilocybinEvidence-based psychotherapiesAcute effectsPhenomenological analysisModerate to strong influencePsilocybin doseBehavioral effectsTherapeutic changeHigher-order themesPlacebo-controlled trialPsilocybinNon-directive supportDouble-blindParticipants' perspectivesDisordersAcute interferenceParticipantsModerators and Mediators of the Relationship Between Social Support and Readiness To Change in OCD
King K, Kichuk S, Pittenger C, Zaboski B. Moderators and Mediators of the Relationship Between Social Support and Readiness To Change in OCD. Journal Of Contemporary Psychotherapy 2025, 1-8. DOI: 10.1007/s10879-025-09692-8.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSocial supportHarm obsessionsSymptom subtypesObsessive-compulsive disorder symptomsEffect of social supportInternalized stigmaDepression severitySymptom factorsPatient-level factorsLinear regression modelsMultiple linear regression modelDepressionObsessionSymptomsRegression modelsModeratelyStigmaThoughtsNegative interactionsSupportIndividualsMediatorsReadinessDisorders#OCD: A Content Analysis of Obsessive-Compulsive Disorder Stereotype Amplification and Misinformation on TikTok
Fitzpatrick M, Moore A, Kichuk S, Pittenger C, Zaboski B. #OCD: A Content Analysis of Obsessive-Compulsive Disorder Stereotype Amplification and Misinformation on TikTok. Cyberpsychology Behavior And Social Networking 2025, 28: 607-615. PMID: 40842159, DOI: 10.1177/21522715251370135.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSocial mediaContent analysisPrevalence of misinformationHealth information ecosystemContent creatorsInformation ecosystemEngagement metricsTikTokEducational contentVideoMisinformationPublic perceptionStereotypesEngagementEngagement levelsAccurate informationMediumViewersCreatorsInformationDialogue
2024
Suicidal Obsessions or Suicidal Ideation? A Case Report and Practical Guide for Differential Assessment
Mattera E, Ching T, Zaboski B, Kichuk S. Suicidal Obsessions or Suicidal Ideation? A Case Report and Practical Guide for Differential Assessment. Cognitive And Behavioral Practice 2024, 31: 259-271. DOI: 10.1016/j.cbpra.2022.09.002.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSuicidal ideationCognitive-behavioral frameworkBehavioral criteriaLow familiarityBehavioral frameworkBehavioral responsesFuture researchCommon measurement toolsExtant literatureOCDCase exampleEvidence-based guideDifferential assessmentObsessionIdeationThoughtMeasurement toolsEmotionsPractical guideFamiliaritySuicidalityInaccurate assessmentInterventionClientsPhenomenologyMechanisms of therapeutic change after psychedelic treatment in OCD
Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObsessive-compulsive disorderMechanisms of therapeutic changeAversive eventsImagery rescriptingPsychedelic treatmentPsychotherapeutic treatmentPsychotherapeutic frameworkSymptom reductionTherapeutic changePsychotherapyNegative emotionsPsychological mechanismsCore beliefsPilot dataNovel treatmentRescriptingEmotionsDisordersSymptomsReprocessingTreatmentBeliefsResistance to first-lineIndividualsInterventionCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Peer-Reviewed Original ResearchSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObsessive-compulsive disorderPrimary outcomeNon-directive supportClinical effectsTreatment-refractory obsessive-compulsive disorderRefractory obsessive-compulsive disorderSingle-dose trialBlinded ratingsWaitlist-controlled trialDose selection strategiesOCD symptom reductionTreatment of OCDEffects of psilocybinSingle-site trialOCD symptomsInstitutional review boardBlinded independent ratersTrials of psilocybinYale-Brown ObsessiveWaitlist control designPrimary endpointMore dosesFuture trialsSingle dosePsilocybin treatment
2023
Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial
Rance M, Zhao Z, Zaboski B, Kichuk S, Romaker E, Koller W, Walsh C, Harris-Starling C, Wasylink S, Adams T, Gruner P, Pittenger C, Hampson M. Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial. Psychiatry Research 2023, 328: 115458. PMID: 37722238, PMCID: PMC10695074, DOI: 10.1016/j.psychres.2023.115458.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObsessive-compulsive disorderAnterior prefrontal cortexControl groupDouble-blind clinical trialDouble-blind trialPrimary outcome measureCompulsive disorderHarm/checkingMechanism of actionYale-Brown ObsessiveSecondary outcomesSessions of neurofeedbackActive groupClinical trialsOutcome measuresPrimary symptomsSymptom ScaleObsessive-compulsive symptomsPrefrontal cortexSymptomsTraining protocolGreater reductionSignificant differencesPatientsSham feedbackSafety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrials
2022
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsion
News
Copy Link
Get In Touch
Copy Link
Contacts
Academic Office Number